LY6

• CAT Number: I031246
• Molecular Formula: C30H27Cl2N3O4
• Molecular Weight: 564.46
• Purity: 98%
• Synonyms: LY6; LY-6; LY 6
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: (E)-1-(1-(5-(3-(2,4-dichlorophenyl)acryloyl)-2-ethoxy-4-hydroxybenzyl)-1,2,5,6-tetrahydropyridin-3-yl)-1H-benzo[d]imidazol-2(3H)-one
• InChI: InChI=1S/C30H27Cl2N3O4/c1-2-39-29-16-28(37)23(27(36)12-10-19-9-11-21(31)15-24(19)32)14-20(29)17-34-13-5-6-22(18-34)35-26-8-4-3-7-25(26)33-30(35)38/h3-4,6-12,14-16,37H,2,5,13,17-18H2,1H3,(H,33,38)/b12-10+
• InChIKey: KXGGLZVQMDYPEO-ZRDIBKRKSA-N
• SMILES: CCOC1=CC(=C(C=C1CN2CCC=C(C2)N3C4=CC=CC=C4NC3=O)C(=O)/C=C/C5=C(C=C(C=C5)Cl)Cl)O

LY6(CAT: I031246) is a potent and selective inhibitor of SHP2, a protein tyrosine phosphatase implicated in various signaling pathways critical for cell growth and survival. It inhibits SHP2 with an IC50 value of 9.8 μM and demonstrates 7-fold selectivity over the closely related SHP1. Quantitative binding assays, including fluorescence titration, thermal shift analysis, and microscale thermophoresis, confirm its direct interaction with SHP2. LY6 holds promise as a lead compound for developing novel therapeutic agents targeting SHP2, with potential applications in cancer and other diseases involving aberrant SHP2 activity. Its specificity and potency make it a valuable tool for biochemical and pharmacological research.